BANK VONTOBEL/CALL/VERTEX PHARMACEUTICALS/400/0.1/21.06.24 | Delayed Deutsche Boerse AG 04:12:21 2024-05-29 EDT | ||
| 4.45 EUR | -3.26% |
|
| Current month | +226.24% | ||
| 1 month | +170.59% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Latest news about VERTEX PHARMACEUTICALS INCORPORATED
More news
| Date | Price | Change |
|---|---|---|
| 24-05-29 | 4.45 | -3.26% |
| 24-05-28 | 4.6 | -20.96% |
| 24-05-27 | 5.82 | +6.20% |
| 24-05-24 | 5.48 | +11.61% |
| 24-05-23 | 4.91 | +3.37% |
Delayed Quote Deutsche Boerse AG
Last update May 29, 2024 at 04:12 am
More quotesStatic data
| Product type | Warrants |
|---|---|
| Buy / Sell | CALL |
| Underlying | VERTEX PHARMACEUTICALS INCORPORATED |
| Issuer | 
Vontobel
|
| WKN | VM3RNF |
| ISIN | DE000VM3RNF8 |
| Date issued | 2023-10-09 |
| Strike | 400 $ |
| Maturity | 2024-06-21 (24 Days) |
| Parity | 10 : 1 |
| Emission price | 2.1 € |
| Emission volume | N/A |
| Settlement | règlement en espèces |
| Currency | EUR |
Technical Indicators
| Highest since issue | 6.17 € |
|---|---|
| Lowest since issue | 1.29 € |
| Delta | 0.88x |
| Omega | 7.693 |
| Premium | 0.94x |
| Gearing | 8.75x |
| Moneyness | 1.117 |
| Difference Strike | -46.88 $ |
| Difference Strike % | -11.72% |
| Spread | 0.17 € |
| Spread % | 3.54% |
| Intrinsic value | 4.326 |
Company Profile
Vertex Pharmaceuticals Incorporated specializes in the research, development and marketing of micromolecular drugs primarily for the treatment of cancers, viral, inflammatory and auto-immune diseases.
Net sales are distributed geographically as follows: the United States (61.2%), Europe (31.5%) and other (7.3%).
Sector
-
Ratings for Vertex Pharmaceuticals Incorporated
Trading Rating
Investor Rating
ESG Refinitiv
B+
Consensus: Vertex Pharmaceuticals Incorporated
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
32
Last Close Price
446.9
USD
Average target price
462.8
USD
Spread / Average Target
+3.57%
- Stock Market
- Warrants
- Warrant
